UBS maintains Ryan Specialty Holdings at Buy, lowers price target to $52 from $55

UBS kept its Buy rating on Ryan Specialty Holdings but reduced its price target to $52 from $55, citing a 14.3% upside from the Nov 2 close. Recent analyst targets for the company range from $40 to $52.

Original reporting
Published Nov 2, 2026, 10:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 10:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
UBS maintains Ryan Specialty Holdings at Buy, lowers price target to $52 from $55 — source image
Decision brief

The 30-second read

Low
01

Why it matters

This is primarily a sell-side valuation update rather than new company-specific operational or financial information.

02

Market read

Traders may adjust near-term sentiment around RYST based on the UBS target reduction, but the lack of new fundamentals limits decision impact.

03

What to watch

The article does not state UBS’s thesis or changes in assumptions, so traders may discount the target cut if it is not tied to new fundamentals.

Relevance 4/10Novelty 3/10Timing: after-hours/next session as traders digest the UBS target cut

Background

The piece summarizes UBS’s latest analyst action on Ryan Specialty Holdings, including a reduced price target and unchanged Buy rating.

Market effects

Limited read-through to specialty insurance brokerage peers, since this is a single-bank target adjustment without new industry data.

No clear regional spillover indicated by the article.

Minimal global relevance; this is a US-listed company analyst note.

Counterpoint

Because the rating is unchanged (Buy), the target cut may have less impact than the market’s broader consensus view of RYST’s valuation.

Key entities

  • Ryan Specialty Holdings

    Subject of the analyst action, with UBS maintaining Buy and lowering the price target to $52.

  • UBS

    Brokerage issuing the maintained rating and revised price target.

Related articles

$RYANMed

Ryan Specialty Holdings Inc (RYAN) (Q3 2026) Earnings Call Highlights: Revenue Growth

Ryan Specialty Holdings (RYAN) reported Q3 2026 revenue growth slowing to 4% from 15% YoY, with adjusted EBITDAC margin down 30 bps to 30.9%. The company cited market challenges, including property pricing declines and increased competition. Management expects continued pressure in Q4 2026 and 2027, with modest margin expansion anticipated. They also discussed growth opportunities in reinsurance and AI-related risks, and potential M&A activity in 2027.

Med

Ryan Specialty grows revenue as property softening squeezes E&S returns

Ryan Specialty reported a 4.7% revenue increase to $790M in Q3 2026, driven by casualty lines, while property revenue declined. Underwriting management grew 5.4%, expanding its share of total revenue. Expenses rose 9.9%, outpacing revenue growth. The company maintained its full-year guidance for mid-single-digit organic revenue growth and reported a 3.8% increase in adjusted EBITDAC to $244.4M.